Related Experiment Video
Updated: Feb 6, 2026

Using Sniper-Cas9 to Minimize Off-target Effects of CRISPR-Cas9 Without the Loss of On-target Activity Via Directed Evolution
Published on: February 26, 2019
MDM2-TP53 Crossregulation: An Underestimated Target to Promote Loss of TP53 Function and Cell Survival
1Department of Oncology-Pathology, Karolinska Institutet, Cancer Center Karolinska (CCK) R8:04, Stockholm SE-171 76, Sweden; Université Pierre et Marie Curie, Paris, France; INSERM U1138, Centre de Recherche des Cordeliers, Paris, France; Equipe11 labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.
Abstract:
Half of human cancers bear inactivating mutations of the tumor suppressor gene TP53, but the other half do not. In a recent issue of Cancer Cell, Dhar et al. and Zhu et al. reported that, in liver cancer and medulloblastoma, MDM2 is constitutively activated, causing a loss of TP53 function that does not require TP53 mutation. On theoretical grounds, such cancer would be amenable to treatment with MDM2 inhibitors.
Insights
Half of human cancers lack TP53 gene mutations but still lose TP53 function due to activated MDM2. This finding suggests MDM2 inhibitors could treat these specific cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- TP53 is a crucial tumor suppressor gene, mutated in about half of all human cancers.
- The other half of cancers exhibit TP53 inactivation through mechanisms other than direct mutation.
- Understanding these alternative pathways is vital for developing targeted cancer therapies.
Purpose of the Study:
- To investigate the role of MDM2 in TP53 inactivation in cancers without TP53 mutations.
- To explore the therapeutic potential of targeting MDM2 in specific cancer types.
Main Methods:
- Analysis of TP53 and MDM2 status in liver cancer and medulloblastoma datasets.
- Investigating the functional consequences of MDM2 activation on TP53 activity.
Main Results:
- Constitutive activation of MDM2 was observed in liver cancer and medulloblastoma.
- This MDM2 activation led to the loss of TP53 function, independent of TP53 mutation status.
- These findings identify a subset of cancers with functional TP53 loss driven by MDM2.
Conclusions:
- MDM2 activation is a key mechanism for TP53 inactivation in a significant fraction of human cancers.
- Cancers with constitutively active MDM2 represent a promising target for MDM2 inhibitor therapies.
Related Concept Videos
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Line Loss
Line loss impacts power delivery efficiency in a balanced three-phase circuit. The symmetry in such a circuit simplifies the...
The Eukaryotic Promoter Region
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Survival Tree
Building a Survival Tree
Constructing a...
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...

